SCHEMBL2053243

SCHEMBL2053243

COc1cc2c(Nc3cnn(CC(=O)Nc4cccc(F)c4F)c3)ncnc2cc1OCCCNCC1CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT4 P35916 4/20 0.62
PDGFRB P09619 4/20 0.62
FLT3 P36888 3/20 0.62
AURKA O14965 11/20 0.59
CSF1R P07333 2/20 0.55
AURKB Q96GD4 3/20 0.52
HDAC3 O15379 4/20 0.50
KDR P35968 4/20 0.50
HDAC4 P56524 4/20 0.50
HDAC1 Q13547 4/20 0.50
HDAC7 Q8WUI4 4/20 0.50
HDAC2 Q92769 4/20 0.50
HDAC10 Q969S8 4/20 0.50
HDAC11 Q96DB2 4/20 0.50
HDAC8 Q9BY41 4/20 0.50
HDAC6 Q9UBN7 4/20 0.50
HDAC9 Q9UKV0 4/20 0.50
HDAC5 Q9UQL6 4/20 0.50
KIT P10721 1/20 0.49
PDGFRA P16234 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2053067 0.91 FLT4 (0.63) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2034330 0.89 FLT4 (0.80) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2053593 0.89 FLT4 (0.69) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2048731 0.89 FLT4 (0.69) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL3427679 0.88 FLT4 (0.61) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL3427672 0.88 FLT4 (0.61) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL3427744 0.88 AURKA (0.62) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2052846 0.88 FLT4 (0.60) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL3427124 0.88 FLT4 (0.69) FLT4PDGFRBFLT3AURKACSF1R
SCHEMBL2054322 0.87 AURKA (0.67) FLT4PDGFRBFLT3AURKACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 FLT4 2898/4885PDGFRB 1544/4885FLT3 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.